Assessing safety and efficacy of TNFi treatment in late onset ankylosing spondylitis: a TURKBIO registry study

Basit Öğe Kaydı
dc.authoridInel, TY/0000-0001-9026-9641
dc.authoridUslu, Sadettin/0000-0001-6266-2454
dc.authorwosidInel, TY/AAC-5112-2022
dc.authorwosidUslu, Sadettin/ABE-8560-2020
dc.contributor.authorUslu, Sadettin
dc.contributor.authorGulle, Semih
dc.contributor.authorSen, Gercek
dc.contributor.authorCefle, Ayse
dc.contributor.authorYilmaz, Sema
dc.contributor.authorKocaer, Sinem Burcu
dc.contributor.authorYuce Inel, Tuba
dc.date.accessioned2024-08-04T20:56:06Z
dc.date.available2024-08-04T20:56:06Z
dc.date.issued2024
dc.departmentİnönü Üniversitesien_US
dc.description.abstractClinical data on the use of tumour necrosis factor inhibitors (TNFi) in late-onset ankylosing spondylitis (LoAS) are limited. The present study aimed to evaluate efficacy, safety, and treatment adherence associated with the initial use of TNFi therapy in biologic naive patients diagnosed with LoAS. Patients whose age of onset was >= 45 years and < 45 years were classified as having LoAS and YoAS, respectively, based on the age of symptom onset. There were 2573 patients with YoAS and 281 LoAS. Baseline disease activity measures were similar between the groups. No significant differences were seen between the two groups in response to treatment and in remaining on the first TNFi at 6, 12 and 24 months. In the LoAS group, the analysis showed that TNFi discontinuation was linked to VAS pain score (HR 1.04; 95% CI 1.01-1.06). Patient groups had similar rates of adverse events (YoAS: 8.7% vs. LoAS: 11.7%). In both biologic naive LoAS and YoAS patients, the study showed that the initial TNFi therapy was equally effective and safe.en_US
dc.description.sponsorshipThanks to all the Turkish departments of rheumatology for reporting to the TURKBIO registry.en_US
dc.identifier.doi10.1038/s41598-024-65180-4
dc.identifier.issn2045-2322
dc.identifier.issue1en_US
dc.identifier.pmid38902436en_US
dc.identifier.scopus2-s2.0-85196393883en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1038/s41598-024-65180-4
dc.identifier.urihttps://hdl.handle.net/11616/102065
dc.identifier.volume14en_US
dc.identifier.wosWOS:001252132200059en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherNature Portfolioen_US
dc.relation.ispartofScientific Reportsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnkylosing spondylitisen_US
dc.subjectLate-onset ankylosing spondylitisen_US
dc.subjectTNFien_US
dc.subject45 yearsen_US
dc.subjectTURKBIOen_US
dc.titleAssessing safety and efficacy of TNFi treatment in late onset ankylosing spondylitis: a TURKBIO registry studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu